NVS - Can Cannabis 2.0 Kickstart Marijuana Stocks?
Second-generation marijuana products including edibles and beverages launch in Canada's marijuana market this month, but marijuana stocks still face stiff headwinds from supply headaches and mounting quarterly losses. Is it finally safe to step up and buy leading players like Canopy Growth (NYSE: CGC) and Organigram (NASDAQ: OGI)?
In this episode of The Motley Fool's Industry Focus: Healthcare, analyst Shannon Jones is joined by healthcare investor Todd Campbell to discuss the latest marijuana news, including Cannabis 2.0, the FDA's latest word on CBD, and the stocks you can consider buying now.
Also, Jones and Campbell weigh in on Novartis' (NYSE: NVS) big cardiovascular disease bet. Will the $9.7 billion it's paying to acquire cholesterol-buster The Medicines Company (NASDAQ: MDCO) prove to be money well spent, or will stiff competition from the likes of Regeneron (NASDAQ: REGN), Amgen (NASDAQ: AMGN), and Esperion Therapeutics (NASDAQ: ESPR) make this deal a bust?